Table 1.

Characteristics of the patients with P. fluorescens recovered from pharyngeal swabsa

PatientAge (yr)/sexUnderlying diseaseNo. of days from admission to first isolationWhite blood cell count on date of first isolation (109 cells/liter)Antibiotic prophylaxis (oral) prior to isolationType (duration ([no. of days]) of antibiotic treatment commenced for febrile neutropeniaNo. of days after first positive swab when antibiotics were started for febrile neutropeniaDate(s) of isolation from pharyngeal swab (day/mo/yr)Patient outcome
161/MMyeloma69.7COL, TMPTZP, VAN, GEN (6)331/01/10Survived
241/FAML360.1COL, TMPNoneNA28/03/10Survived
364/MAML180.5COL, TMP, CLRNoneNA28/03/10Survived
421/FALL350.3COL, TMPTZP, GEN (26)407/03/10, 28/03/10Survived
554/FHL110.3COLTZP, GEN, VAN (6)107/03/10Survived
647/MAML51.2COLTZP, GEN (6)707/03/10Survived
746/MCMML110.7COL, PEN, CIPNoneNA07/03/10Survived
847/MALL360.8COL, TMP, PENTZP, GEN (10)007/03/10Survived
943/FMDS40.0COL, TMPTZP, GEN (3)614/03/10Died
  • a F, female; M, male; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; HL, Hodgkin lymphoma; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; COL, colistin; TMP, trimethoprim-sulfamethoxazole; CLR, clarithromycin; TZP, piperacillin-tazobactam; PEN, penicillin V; CIP, ciprofloxacin; GEN, gentamicin; VAN, vancomycin; NA, not applicable.